GT Biopharma Inc (GTBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GT Biopharma Inc (GTBP) has a cash flow conversion efficiency ratio of -0.326x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.47 Million) by net assets ($7.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of GT Biopharma Inc to measure how much of total assets are equity-financed.
GT Biopharma Inc - Cash Flow Conversion Efficiency Trend (1985–2025)
This chart illustrates how GT Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GT Biopharma Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
GT Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GT Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oxbridge Re Holdings Ltd
NASDAQ:OXBR
|
0.032x |
|
Origin Agritech Limited
STU:39O1
|
N/A |
|
Noviqtech Ltd
AU:NVQ
|
2.158x |
|
Binasat Communications Bhd
KLSE:0195
|
-0.176x |
|
Jeonjinbio Co. Ltd
KQ:110020
|
0.018x |
|
Australian Oilseeds Holdings Limited Ordinary Shares
NASDAQ:COOT
|
-0.261x |
|
Dfcity Group Bhd
KLSE:5165
|
0.025x |
|
Karnalyte Resources Inc.
TO:KRN
|
-0.024x |
Annual Cash Flow Conversion Efficiency for GT Biopharma Inc (1985–2025)
The table below shows the annual cash flow conversion efficiency of GT Biopharma Inc from 1985 to 2025. For the full company profile with market capitalisation and key ratios, see GT Biopharma Inc (GTBP) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.79 Million | $-12.91 Million | -2.232x | -128.88% |
| 2024-12-31 | $-1.67 Million | $-12.90 Million | 7.727x | +752.58% |
| 2023-12-31 | $7.48 Million | $-8.85 Million | -1.184x | +8.70% |
| 2022-12-31 | $11.73 Million | $-15.22 Million | -1.297x | -82.07% |
| 2021-12-31 | $21.91 Million | $-15.61 Million | -0.712x | -388.69% |
| 2020-12-31 | $-29.43 Million | $-7.26 Million | 0.247x | +30.21% |
| 2019-12-31 | $-19.31 Million | $-3.66 Million | 0.189x | +120.18% |
| 2018-12-31 | $11.37 Million | $-10.68 Million | -0.939x | -4252.64% |
| 2017-12-31 | $251.69 Million | $-5.43 Million | -0.022x | -121.15% |
| 2016-12-31 | $-18.92 Million | $-1.93 Million | 0.102x | +10.74% |
| 2015-12-31 | $-50.57 Million | $-4.66 Million | 0.092x | +55.72% |
| 2014-12-31 | $-29.57 Million | $-1.75 Million | 0.059x | -15.25% |
| 2013-12-31 | $-6.33 Million | $-442.00K | 0.070x | -55.20% |
| 2012-12-31 | $-6.34 Million | $-987.00K | 0.156x | -17.49% |
| 2011-12-31 | $-5.10 Million | $-963.00K | 0.189x | -32.74% |
| 2010-12-31 | $-5.47 Million | $-1.53 Million | 0.281x | +71.46% |
| 2009-12-31 | $-5.72 Million | $-937.00K | 0.164x | +256.45% |
| 2008-12-31 | $-3.68 Million | $-169.00K | 0.046x | +127.71% |
| 2007-12-31 | $1.63 Million | $-270.00K | -0.166x | +95.18% |
| 2006-12-31 | $195.00K | $-671.00K | -3.441x | -481.67% |
| 2005-12-31 | $3.54 Million | $-2.09 Million | -0.592x | -229.06% |
| 2004-12-31 | $5.80 Million | $-1.04 Million | -0.180x | +31.70% |
| 2003-12-31 | $870.00K | $-229.00K | -0.263x | +68.19% |
| 2002-12-31 | $1.22 Million | $-1.01 Million | -0.828x | +69.05% |
| 2001-12-31 | $533.00K | $-1.43 Million | -2.674x | -180.15% |
| 2000-12-31 | $4.07 Million | $-3.89 Million | -0.954x | -3.60% |
| 1999-12-31 | $2.69 Million | $-2.48 Million | -0.921x | -27.55% |
| 1998-12-31 | $7.20 Million | $-5.20 Million | -0.722x | -2.31% |
| 1997-12-31 | $6.80 Million | $-4.80 Million | -0.706x | +26.13% |
| 1996-12-31 | $4.50 Million | $-4.30 Million | -0.956x | +22.47% |
| 1995-12-31 | $4.30 Million | $-5.30 Million | -1.233x | -2164.53% |
| 1994-12-31 | $6.70 Million | $400.00K | 0.060x | +110.45% |
| 1993-12-31 | $2.80 Million | $-1.60 Million | -0.571x | -391.43% |
| 1992-12-31 | $4.30 Million | $-500.00K | -0.116x | -167.44% |
| 1991-12-31 | $4.60 Million | $-200.00K | -0.043x | -123.19% |
| 1990-12-31 | $4.80 Million | $900.00K | 0.188x | +4.46% |
| 1989-12-31 | $3.90 Million | $700.00K | 0.179x | +474.36% |
| 1988-12-31 | $3.20 Million | $100.00K | 0.031x | +93.75% |
| 1987-12-31 | $3.10 Million | $50.00K | 0.016x | +111.29% |
| 1986-12-31 | $2.80 Million | $-400.00K | -0.143x | -47.62% |
| 1985-12-31 | $3.10 Million | $-300.00K | -0.097x | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more